Cargando…

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers

Triple-negative breast cancers (TNBC) are characterized by frequent alterations in the PI3K/AKT/mTOR signaling pathway. In this study, we analyzed PI3K pathway activation in 67 patient-derived xenografts (PDX) of breast cancer and investigated the anti-tumor activity of the mTOR inhibitor everolimus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatem, Rana, Botty, Rania El, Chateau-Joubert, Sophie, Servely, Jean-Luc, Labiod, Dalila, de Plater, Ludmilla, Assayag, Franck, Coussy, Florence, Callens, Céline, Vacher, Sophie, Reyal, Fabien, Cosulich, Sabina, Diéras, Véronique, Bièche, Ivan, Marangoni, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217012/ https://www.ncbi.nlm.nih.gov/pubmed/27374081 http://dx.doi.org/10.18632/oncotarget.10195

Ejemplares similares

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition
por: El Botty, Rania, et al.
Publicado: (2018)

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast
por: Bièche, Ivan, et al.
Publicado: (2021)

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
por: Coussy, Florence, et al.
Publicado: (2020)

Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant
por: Jacquemetton, Julien, et al.
Publicado: (2021)

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer
por: Spasojevic, Caroline, et al.
Publicado: (2018)

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer
por: Tury, Sandrine, et al.
Publicado: (2016)

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
por: Montaudon, Elodie, et al.
Publicado: (2021)

HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers
por: El‐Botty, Rania, et al.
Publicado: (2023)

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings
por: Bieche, Ivan, et al.
Publicado: (2014)

Clinical value of R-spondins in triple-negative and metaplastic breast cancers
por: Coussy, F, et al.
Publicado: (2017)

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
por: Coussy, F., et al.
Publicado: (2020)

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers
por: ter Brugge, Petra, et al.
Publicado: (2023)

Predictive Gene Signature of Response to the Anti-TweakR mAb PDL192 in Patient-Derived Breast Cancer Xenografts
por: de Plater, Ludmilla, et al.
Publicado: (2014)

Altered Expression of Three EGFR Posttranslational Regulators MDGI, MIG6, and EIG121 in Invasive Breast Carcinomas
por: Meseure, Didier, et al.
Publicado: (2020)

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
por: Legrier, Marie-Emmanuelle, et al.
Publicado: (2016)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?
por: Cizeron-Clairac, Geraldine, et al.
Publicado: (2015)

Molecular profiling of patient-derived breast cancer xenografts
por: Reyal, Fabien, et al.
Publicado: (2012)

ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin
por: Tanaka, Iris, et al.
Publicado: (2020)

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2020)

Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis
por: Labrosse, Julie, et al.
Publicado: (2020)

Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer
por: Liang, Xu, et al.
Publicado: (2018)

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance
por: Montaudon, Elodie, et al.
Publicado: (2020)

Prognostic value of a newly identified MALAT1 alternatively spliced transcript in breast cancer
por: Meseure, Didier, et al.
Publicado: (2016)

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft
por: Passeri, Thibault, et al.
Publicado: (2022)

The Presence of an In Situ Component on Pre-Treatment Biopsy Is Not Associated with Response to Neoadjuvant Chemotherapy for Breast Cancer
por: Labrosse, Julie, et al.
Publicado: (2021)

PIK3R1 underexpression is an independent prognostic marker in breast cancer
por: Cizkova, Magdalena, et al.
Publicado: (2013)

Spontaneous mouse lymphoma in patient-derived tumor xenografts: The importance of systematic analysis of xenografted human tumor tissues in preclinical efficacy trials
por: Chateau-Joubert, Sophie, et al.
Publicado: (2021)

Distinct expression profiles and functions of Kindlins in breast cancer
por: Azorin, Paula, et al.
Publicado: (2018)

ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels
por: Rondeau, S, et al.
Publicado: (2015)

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2019)

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
por: García-Martínez, Juan M., et al.
Publicado: (2009)

Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization
por: Vallerand, David, et al.
Publicado: (2016)

HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens
por: Laas, Enora, et al.
Publicado: (2021)

ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis
por: Dumortier, Mandy, et al.
Publicado: (2018)

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
por: El-Botty, Rania, et al.
Publicado: (2023)

Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients
por: Karam, Manale, et al.
Publicado: (2014)

Differential Expression of Genes Involved in Metabolism and Immune Response in Diffuse and Intestinal Gastric Cancers, a Pilot Ptudy
por: Perrot-Applanat, Martine, et al.
Publicado: (2022)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
por: Liang, Xu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6jo9bf328ufegiuvq656cvnnq7